| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. | Chief Accounting Officer | Common Stock | 4.12K | $9.23K | $2.24 | Nov 14, 2025 | Direct |
| Acrivon Therapeutics, Inc. | Chief Accounting Officer | Stock Option (Right to Buy) | 31.9K | Mar 1, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2025 | 1 | -$222 | 4 | Nov 18, 2025 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | Aug 14, 2025 | 1 | -$138 | 4 | Aug 18, 2025 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | May 14, 2025 | 1 | -$113 | 4 | May 16, 2025 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | Mar 1, 2025 | 1 | $0 | 4 | Mar 4, 2025 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | Feb 14, 2025 | 1 | -$629 | 4 | Feb 19, 2025 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2024 | 1 | -$784 | 4 | Nov 18, 2024 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | Aug 14, 2024 | 1 | -$695 | 4 | Aug 16, 2024 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | May 14, 2024 | 1 | -$828 | 4 | May 16, 2024 | Chief Accounting Officer |
| ACRV | Acrivon Therapeutics, Inc. | May 13, 2024 | 0 | $0 | 3 | May 16, 2024 | Chief Accounting Officer |